FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC

Home / Blog / FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC
FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC
May 21, 2020May 21, 2020
0

The U.S. Food and Drug Administration (FDA) has approved Genentech‘s Tecentriq (atezolizumab) as an initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors produce high levels of the PD-L1 protein but have no alterations in the EGFR or ALK genes. Approval was based on findings from the IMpower110 Phase 3 trial (NCT02409342), which showed that Tecentriq significantly extended patients’ survival compared with chemotherapy, without impacting quality of life. This is the second immunotherapy regimen…

You must be logged in to read/download the full post.